Results 221 to 230 of about 139,167 (351)

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) [PDF]

open access: bronze, 2004
Veronika Ballová   +14 more
openalex   +1 more source

Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population‐based cohort study

open access: yesBritish Journal of Haematology, EarlyView.
Treatment‐related infertility is of great concern to younger long‐term survivors of acute leukaemia (AL). The literature on fertility outcomes in adult long‐term AL survivors is limited, mainly focused on stem cell transplantation or childhood leukaemia, with little information on the use of assisted reproduction technology.
Nanna N. Nielsen   +10 more
wiley   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study. [PDF]

open access: yesSci Rep
Alalawi M   +22 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy